Armata pharmaceuticals, inc. (APHB)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities:
Net loss

-5,078

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-6,955

-4,321

-3,617

-

-2,771

-9,696

-3,134

-2,352

-779

-6,461

-3,246

-9,500

-2,375

-3,851

-3,112

-2,231

5,439

10,769

-14,493

-664

21,207

13,873

-11,307

458

-48,753

-14,643

-1,645

Adjustments required to reconcile net loss to net cash used in operating activities:
Change in fair value of Series B preferred stock derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,105

-

-

-

-

-

-

-

-

Warrants and other allocable expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

227

204

-

0

0

213

-

-

-

-

-

-

-

-

Amortization of note discount and patents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

311

Warrants issued as investment fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Depreciation

295

302

366

583

100

212

337

713

89

88

85

85

85

93

87

85

73

82

100

59

58

68

-27

68

18

16

21

24

21

Stock-based compensation

1,044

1,047

2,499

626

99

-1

8

-83

122

132

98

299

171

297

334

548

816

230

148

53

52

61

246

234

234

231

248

804

154

Warrants issued to placement agents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Amortization of patents

-

-

-

-

8

-

-

-

8

8

8

7

8

8

8

7

8

8

8

7

8

8

8

7

8

-

-

-

-

Charge for common stock issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

3,000

0

Non-cash interest expense

159

-

-

-

-

-

-

-

-

0

4

8

10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-

0

0

1,128

-11

1,965

-106

-56

-79

-

-37

1,920

114

2,135

1,032

-35

1,406

636

7,738

6,256

-4,690

27,974

397

17,621

-8,773

3,020

-46,380

-6,057

87

Changes in operating assets and liabilities:
Award receivable

1,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-cash adjustments, net

159

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

4

-111

85

40

0

-100

73

-109

124

4

-140

8

129

-12

Tax refund

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-618

Accounts payable and accrued liabilities

-195

-203

-572

-1,052

453

-371

648

-72

-61

-243

-583

519

-531

190

-293

2

507

-112

-192

23

158

-672

370

690

-1,365

907

-333

260

-380

Accrued compensation

-114

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent and lease liabilities, net

122

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred award liability

859

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation

-

-

-

-

482

-

-

-

-355

-

-

-

-

-

140

69

-241

236

170

-112

-122

-

-

-

0

-

-

-

-

Prepaid expenses and other current assets

80

-149

-256

-99

156

380

46

-373

284

-11

-18

-34

-318

-296

-6

10

45

-264

272

100

74

-109

-78

181

48

-4

66

-132

219

Net cash used in operating activities

-4,232

-2,729

-4,567

-5,666

-2,620

-3,195

-2,020

-1,876

-3,536

-2,369

-593

-2,931

-3,299

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest on loan notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

9

128

96

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,131

-2,892

-3,085

-2,317

-2,497

-2,662

-2,305

-3,200

-2,627

-3,054

-3,691

-1,412

-2,494

-1,267

-1,119

Investing activities:
Purchases of property and equipment

104

21

-65

261

7

-

-

-

-

18

33

2

5

13

29

125

112

50

116

9

35

5

137

831

229

5

32

65

0

Net cash used in investing activities

-104

72

65

2,747

-7

-

-

-

-

-18

-33

-2

-5

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-29

-125

-112

-50

-116

-9

-35

-5

-137

-831

-229

-5

-32

-65

0

Financing activities:
Payment of deferred consideration for asset acquisition

-1,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of common stock, net of offering costs

23,331

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from sale of common stock, net of offering costs

-

-

-

-

-

-

-

-

6,409

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercises of warrants

81

-

-

-

5

-

-

-

198

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from stock issuance under employee stock purchase plan

-

-

-

-

-

-

-

-

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments on note payable

-

-

-

-

-

-

-

-

-

-

305

0

205

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

22,412

0

0

8,970

5

-

-

-

6,610

-206

-611

9,693

-205

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

18,076

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,384

-

-

-

-

-

-

-

-

Net proceeds from March 2015 financing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from Series B redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

7,000

0

Proceeds from convertible loan notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,024

976

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-1

397

12,384

-

-

0

0

16,913

0

7,998

976

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-2,622

-

-

-

3,074

-2,593

-1,237

6,760

-3,509

1,744

-3,177

971

-3,197

-2,367

-2,614

-2,274

10,044

-3,205

-2,764

-3,885

-3,920

15,496

-2,526

6,666

-143

Supplemental schedule of non-cash investing and financing activities:
Property and equipment included in accounts payable

9

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of Series B redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

133

1,725

949

7,163

1,828

338

-

-

-

314

-

-

-

-

Fair value of warrant liability upon issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-1

4,211

-

-

-

-

-

-

-

-

Unpaid offering costs

471

-

-

-

-

-

-

-

223

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of warrant liability upon issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Conversion of convertible loan notes and accrued interest to Series B redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,698

0

618

0

Accretion of Series B redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0